Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 3
1947 2
1948 3
1949 6
1950 3
1951 11
1952 6
1953 3
1954 7
1955 2
1956 1
1957 4
1958 5
1959 2
1960 5
1962 1
1964 1
1965 1
1967 1
1969 1
1970 2
1971 1
1976 1
1978 2
1986 1
1988 3
1989 1
1991 1
1992 3
1993 1
1994 2
1995 1
1996 1
1997 2
2000 2
2001 1
2003 1
2004 1
2005 1
2006 1
2007 1
2008 3
2009 4
2010 1
2011 4
2012 6
2013 2
2014 1
2015 1
2016 4
2017 10
2018 6
2019 9
2020 11
2021 14
2022 15
2023 23
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

209 results

Results by year

Filters applied: . Clear all
Page 1
Persistent GDNF Expression 45 Months after Putaminal Infusion of AAV2-GDNF in a Patient with Parkinson's Disease.
Heiss JD, Ray-Chaudhury A, Kleiner DE, Ehrlich DJ, Scott G, Edwards NA, Goldstein DS, Hammoud DA, Hadaczek P, Van Laar VS, Graff SA, Herscovitch P, Lungu C, Hallett M, Lonser RR, Zaghloul KA, Bankiewicz KS. Heiss JD, et al. Among authors: graff sa. Mov Disord. 2024 May 8. doi: 10.1002/mds.29820. Online ahead of print. Mov Disord. 2024. PMID: 38718138
Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines.
Groheux D, Vaz SC, Ulaner GA, Cook GJR, Woll JPP, Mann RM, Poortmans P, Cardoso F, Jacene H, Graff SL, Rubio IT, Peeters MV, Dibble EH, de Geus-Oei LF. Groheux D, et al. Among authors: graff sl. Eur J Nucl Med Mol Imaging. 2024 May 2. doi: 10.1007/s00259-024-06694-x. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 38693453 No abstract available.
The Genomic, Transcriptomic, and Immunologic Landscape of HRAS Mutations in Solid Tumors.
Kareff SA, Trabolsi A, Krause HB, Samec T, Elliott A, Rodriguez E, Olazagasti C, Watson DC, Bustos MA, Hoon DSB, Graff SL, Antonarakis ES, Goel S, Sledge G, Lopes G. Kareff SA, et al. Among authors: graff sl. Cancers (Basel). 2024 Apr 19;16(8):1572. doi: 10.3390/cancers16081572. Cancers (Basel). 2024. PMID: 38672653 Free PMC article.
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers.
Muquith M, Espinoza M, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis ES, Graff SL, Hall MJ, Borghaei H, Hoon DSB, Liu SV, Ma PC, McKay RR, Wise-Draper T, Marshall J, Sledge GW, Spetzler D, Zhu H, Hsiehchen D. Muquith M, et al. Among authors: graff sl. Nat Cancer. 2024 Mar 25. doi: 10.1038/s43018-024-00752-x. Online ahead of print. Nat Cancer. 2024. PMID: 38528112
αKG-mediated carnitine synthesis promotes homologous recombination via histone acetylation.
Uboveja A, Huang Z, Buj R, Amalric A, Wang H, Tangudu NK, Cole AR, Megill E, Kantner D, Chatoff A, Ahmad H, Marcinkiewicz MM, Disharoon JA, Graff S, Dahl ES, Hempel N, Stallaert W, Sidoli S, Bitler BG, Long DT, Snyder NW, Aird KM. Uboveja A, et al. Among authors: graff s. bioRxiv [Preprint]. 2024 Feb 11:2024.02.06.578742. doi: 10.1101/2024.02.06.578742. bioRxiv. 2024. PMID: 38370789 Free PMC article. Preprint.
RNA polymerase II promotes the organization of chromatin following DNA replication.
Bandau S, Alvarez V, Jiang H, Graff S, Sundaramoorthy R, Gierlinski M, Toman M, Owen-Hughes T, Sidoli S, Lamond A, Alabert C. Bandau S, et al. Among authors: graff s. EMBO Rep. 2024 Mar;25(3):1387-1414. doi: 10.1038/s44319-024-00085-x. Epub 2024 Feb 12. EMBO Rep. 2024. PMID: 38347224 Free PMC article.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free article. Clinical Trial.
209 results